Prevalence of methotrexate intolerance among patients with rheumatoid arthritis in Erbil city using methotrexate intolerance severity score


  • Zhala Kakamin Mawlood
  • Dashty Abbas Albustany



Methotrexate, Methotrexate intolerance severity score (MISS), Rheumatoid arthritis


Background and objectives:  Rheumatoid arthritis is classified as an autoimmune disease characterized by inflammation of the joints and membranes surrounding the joints.The aim of this study was to find the frequency of methotrexate intolerance among rheumatoid arthritis patients and to detect factors contributing to intolerance.

Methods: An observational cross-sectional study was conducted in Rizgary and Hawler Teaching Hospital in Erbil/ Iraq. The study period started from the 1st of July 2021 to the 1st of July 2022. A convenient sample of hundred patients was included in the study. A validated version of the methotrexate intolerance severity score questionnaire was used for data collection. Each element in the methotrexate intolerance severity score questionnaire was given a score ranging from 0-3 depending on the absence of symptoms or the presence of mild, moderate or severe symptoms. The intolerance was diagnosed based on a cut-off score of 6 and more.

Results: Females constituted 93% of the sample, 49% were obese, and only 13% were smokers. Among the rheumatoid arthritis patients, 66% tolerated Methotrexate, and only 34% did not tolerate the treatment.  The oral dose was tolerated by 71%, and the only significant relation(p=0.050) was reported for the route of Methotrexate administration. The differences were significant for restlessness (p<0.001), crying (p=0.002), irritability(p<0.001), and not taking medication.

Conclusions: The study concluded that Methotrexate intolerance is prevalent among Rheumatoid arthritis patients in Erbil city. The prevalence of intolerance was significant among steroid users.


Download data is not yet available.


Kyburz, Diego, et al. "The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study." Rheumatology 50.6 (2011): 1106-10.

Alamanos, Yannis, and Alexandros A. Drosos. "Epidemiology of adult rheumatoid arthritis." Autoimmunity reviews 4.3 (2005): 130-6.?

Mathkhor, Abdulsatar J., Abdulnasser H. Abdullah, and Amer S. Khoudhairy. "Demographic, clinical, and serological features of Iraqi patients with rheumatoid arthritis: evaluation of 470 patients." Int J Clin Rheumatol 16.3 (2021): 99-103.?

Heidari B, Lotfi Z, Firouzjahi AR, Heidari P. Comparing the diagnostic value of anti-cyclic citrullinatied peptid antibody and rheumatoid factor for rheumatoid arthritis. Res med. 2010;33(3):156–61.

Heidari B, Firouzjahi A, Heidari P, Hajian K. The prevalence and diagnostic performance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: the predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis. Ann Saudi Med. 2009;29(6):467–70.

Smolen, Josef S., et al. "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2019 update." Annals of the rheumatic diseases 79.6 (2020): 685-699.?

Wasserman AM. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2011; 84(11):1245–52.

Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014; 2014(6):CD000957.

Dhir V, Sandhu A, Kaur J, et al. Comparison of two different folic acid doses with methotrexate—a randomized controlled trial (FOLVARI Study). Arthritis Res Ther. 2015 ;17(1):156.

Chan ES, Cronstein BN. Mechanisms of action of methotrexate. Bull Hosp Jt Dis .2013;71 Suppl 1: S5-8.

Amaral JM, Brito MJM, Kakehasi AM. Cultural Adaptation and Validation of the Methotrexate Intolerance Severity Score in Brazilian Portuguese for Adults with Rheumatoid Arthritis. J Clin Rheumatol. 2021 1;27(6S):S168-72.

Bulatovic M, Heijstek MW, Verkaaik M, et al. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis and Rheumatism. 2011;63(7):2007-13.

Jonathan Kay, Katherine S. Upchurch. ACR/EULAR 2010 rheumatoid arthritis classification criteria, Rheumatology.2012;51, (6): vi5–vi9.

Gramling A, O'Dell JR. Initial management of rheumatoid arthritis. Rheum Dis Clin N Am. 2012; 38(2):311–25.

Kougkas N, Dara A, Pagkopoulou E, et al. Methotrexate induced neurotoxicity in a patient with rheumatoid arthritis on rituximab therapy: a case based review. Rheumatology International. 2022; 42:1849–54.

Almalag H, Abouzaid HH, Alnaim L, et al. Risk Factors Associated with Methotrexate Intolerance in Rheumatoid Arthritis Patients Open Access Rheumatol. 2020;12:193-202.:

Fatimah N, Salim B, Nasim A, Hussain K, Gul H, Niazi S. Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire). Clin Rheumatol. 2016:1341-5.

?alasan MB, van den Bosch OF, Creemers MC, et al. Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther. 2013;15(6): R217.

Albaqami J, Alshalhoub R, Almalag H, et al. Prevalence of methotrexate intolerance among patients with rheumatoid arthritis using the Arabic version of the methotrexate intolerance severity score. Int J Rheum Dis. 2019 ;22(8):1572-7.

Al-Malaq HM, Al-Arfaj HF, Al-Arfaj AS. Adverse drug reactions caused by methotrexate in Saudi population. Saudi Pharm J. 2012;20(4):301-5.




How to Cite

Mawlood, Z. K. ., & Albustany, D. A. . (2024). Prevalence of methotrexate intolerance among patients with rheumatoid arthritis in Erbil city using methotrexate intolerance severity score. AMJ (Advanced Medical Journal) , 9(1), 97-105.